TY - JOUR
T1 - Mechanistic role of boswellic acids in Alzheimer's disease
T2 - Emphasis on anti-inflammatory properties
AU - Siddiqui, Aisha
AU - Shah, Zahoor
AU - Jahan, Rao Nargis
AU - Othman, Iekhsan
AU - Kumari, Yatinesh
N1 - Funding Information:
We thank Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia for School Collaborative Grant 2021 ( MED/SCG2021/07 ; SED-000064 ), for the financial support to our work on the neurodegeneration and possible alternative therapeutic targets, which was the starting point of this review article.
Publisher Copyright:
© 2021
PY - 2021/12
Y1 - 2021/12
N2 - The resin/gum of Boswellia species belonging to the family of Burseraceae is a naturally occurring mixture of bioactive compounds, which was traditionally used as a folk medicine to treat conditions like chronic inflammation. Several research studies have also explored its’ therapeutic potential against multiple neurodegenerative diseases such as Alzheimer's disease (AD). The main chemical constituents of this gum include boswellic acids (BAs) like 3-O-acetyl-11-keto-β boswellic acid (AKBA) that possess potent anti-inflammatory and neuroprotective properties in AD. It is also involved in inhibiting the acetylcholinesterase (AChE) activity in the cholinergic pathway and improve choline levels as well as its binding with nicotinic receptors to produce anti-inflammatory effects. Multiple shreds of evidence have demonstrated that BAs modulate key molecular targets and signalling pathways like 5-lipoxygenase/cyclooxygenase, Nrf2, NF-kB, cholinergic, amyloid-beta (Aβ), and neurofibrillary tangles formation (NFTs) that are involved in AD progression. The present review focuses on the possible mechanistic therapeutic role of BAs in modulating the 5-LOX/COX pathway in arachidonic acid metabolism, activating Nrf2 through binding of ARE, inhibiting NF-kB and AChE activity. In addition, an inhibition of amyloid plaques (Aβ) and neurofibrillary tangles (NFTs) induced neurotoxicity and neuroinflammation in AD by BAs is also discussed in this review. We have also highlighted that BAs possess beneficial effects in AD by targeting multiple molecular pathways and makes it an emerging drug candidate for treating neurodegenerative diseases.
AB - The resin/gum of Boswellia species belonging to the family of Burseraceae is a naturally occurring mixture of bioactive compounds, which was traditionally used as a folk medicine to treat conditions like chronic inflammation. Several research studies have also explored its’ therapeutic potential against multiple neurodegenerative diseases such as Alzheimer's disease (AD). The main chemical constituents of this gum include boswellic acids (BAs) like 3-O-acetyl-11-keto-β boswellic acid (AKBA) that possess potent anti-inflammatory and neuroprotective properties in AD. It is also involved in inhibiting the acetylcholinesterase (AChE) activity in the cholinergic pathway and improve choline levels as well as its binding with nicotinic receptors to produce anti-inflammatory effects. Multiple shreds of evidence have demonstrated that BAs modulate key molecular targets and signalling pathways like 5-lipoxygenase/cyclooxygenase, Nrf2, NF-kB, cholinergic, amyloid-beta (Aβ), and neurofibrillary tangles formation (NFTs) that are involved in AD progression. The present review focuses on the possible mechanistic therapeutic role of BAs in modulating the 5-LOX/COX pathway in arachidonic acid metabolism, activating Nrf2 through binding of ARE, inhibiting NF-kB and AChE activity. In addition, an inhibition of amyloid plaques (Aβ) and neurofibrillary tangles (NFTs) induced neurotoxicity and neuroinflammation in AD by BAs is also discussed in this review. We have also highlighted that BAs possess beneficial effects in AD by targeting multiple molecular pathways and makes it an emerging drug candidate for treating neurodegenerative diseases.
KW - Alzheimer's disease
KW - Boswellic acids
KW - Inflammatory mediators
KW - Neuroinflammation
KW - Signalling pathways
UR - https://www.scopus.com/pages/publications/85116006676
U2 - 10.1016/j.biopha.2021.112250
DO - 10.1016/j.biopha.2021.112250
M3 - Review Article
C2 - 34607104
AN - SCOPUS:85116006676
SN - 0753-3322
VL - 144
JO - Biomedicine & Pharmacotherapy
JF - Biomedicine & Pharmacotherapy
M1 - 112250
ER -